Samuel Jack Vidal, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| GATA2 Transcription Factor | 1 | 2015 | 151 | 0.570 |
Why?
|
| Antibodies, Neutralizing | 1 | 2021 | 1367 | 0.500 |
Why?
|
| Cytological Techniques | 1 | 2014 | 224 | 0.490 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 2286 | 0.450 |
Why?
|
| Neoplastic Stem Cells | 2 | 2014 | 1366 | 0.370 |
Why?
|
| Pandemics | 1 | 2021 | 5014 | 0.250 |
Why?
|
| Cross Reactions | 1 | 2021 | 880 | 0.200 |
Why?
|
| Somatomedins | 1 | 2015 | 196 | 0.150 |
Why?
|
| Prostatic Neoplasms | 2 | 2014 | 10083 | 0.140 |
Why?
|
| Niacinamide | 1 | 2015 | 430 | 0.130 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2015 | 275 | 0.130 |
Why?
|
| Vascular Diseases | 1 | 2020 | 1056 | 0.130 |
Why?
|
| Phenylurea Compounds | 1 | 2015 | 541 | 0.120 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2015 | 3724 | 0.120 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2015 | 5004 | 0.110 |
Why?
|
| Receptor, Insulin | 1 | 2015 | 848 | 0.110 |
Why?
|
| Staining and Labeling | 1 | 2014 | 1133 | 0.100 |
Why?
|
| Fibroblast Growth Factors | 1 | 2015 | 854 | 0.100 |
Why?
|
| Taxoids | 1 | 2012 | 707 | 0.090 |
Why?
|
| Thrombosis | 1 | 2020 | 2631 | 0.090 |
Why?
|
| Hedgehog Proteins | 1 | 2012 | 748 | 0.090 |
Why?
|
| Receptors, Notch | 1 | 2012 | 747 | 0.090 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2015 | 1902 | 0.070 |
Why?
|
| Antigens, CD | 1 | 2015 | 4273 | 0.070 |
Why?
|
| Flow Cytometry | 1 | 2014 | 6263 | 0.060 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2020 | 123 | 0.050 |
Why?
|
| Liver Neoplasms | 1 | 2015 | 3843 | 0.050 |
Why?
|
| Complement Activation | 1 | 2020 | 459 | 0.050 |
Why?
|
| Cell Proliferation | 1 | 2015 | 10883 | 0.050 |
Why?
|
| Male | 6 | 2021 | 342721 | 0.040 |
Why?
|
| Platelet Activation | 1 | 2020 | 637 | 0.040 |
Why?
|
| Signal Transduction | 3 | 2015 | 23898 | 0.040 |
Why?
|
| Receptors, Somatomedin | 1 | 2015 | 65 | 0.040 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2015 | 248 | 0.040 |
Why?
|
| Macaca mulatta | 1 | 2020 | 2353 | 0.030 |
Why?
|
| Spheroids, Cellular | 1 | 2015 | 361 | 0.030 |
Why?
|
| Mice | 3 | 2015 | 79120 | 0.030 |
Why?
|
| Humans | 6 | 2021 | 657367 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2015 | 13659 | 0.030 |
Why?
|
| Animals | 4 | 2020 | 168507 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2020 | 3443 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2012 | 1919 | 0.020 |
Why?
|
| Disease Progression | 2 | 2015 | 12818 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2015 | 16679 | 0.020 |
Why?
|
| Adult | 1 | 2021 | 205617 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2012 | 2845 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2015 | 6745 | 0.020 |
Why?
|
| Cytokines | 1 | 2020 | 6985 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2012 | 1378 | 0.020 |
Why?
|
| Macrophages | 1 | 2020 | 5657 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2012 | 2518 | 0.020 |
Why?
|
| Gene Expression | 1 | 2015 | 8065 | 0.010 |
Why?
|
| Lung | 1 | 2020 | 8941 | 0.010 |
Why?
|
| Inflammation | 1 | 2020 | 9137 | 0.010 |
Why?
|
| Survival Rate | 1 | 2015 | 13233 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 9468 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2012 | 19447 | 0.010 |
Why?
|
| Apoptosis | 1 | 2012 | 10267 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 57560 | 0.010 |
Why?
|
| Female | 2 | 2020 | 363990 | 0.010 |
Why?
|
| Aged | 1 | 2015 | 156344 | 0.000 |
Why?
|